|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
8.320 USD |
-2.69% | +14.76% | -28.64% | |
Published on 05/13/2025 at 22:05
Presenter Speech
Alec Stranahan (Analysts)
Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference. My name is Alec
E
|
Intellia Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04:20 PM |
10:05pm |
|
|
Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating |
May. 09 |
MT |
|
RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk |
May. 09 |
MT |
|
Intellia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 |
May. 08 |
|
|
Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 08 |
CI |
|
Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research |
Apr. 21 |
MT |
|
Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21 |
Apr. 21 |
MT |
|
RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk |
Apr. 03 |
MT |
|
Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2Â Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy |
Apr. 03 |
RE |
|
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin Amyloidosis with Polyneuropathy |
Apr. 03 |
CI |
|
Intellia Therapeutics’ Gene-Editing Drug Gets FDA Designation |
Mar. 26 |
MT |
|
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) |
Mar. 26 |
RE |
|
Intellia Therapeutics, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy |
Mar. 26 |
CI |
|
Intellia Therapeutics, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 03:00 PM |
Mar. 11 |
|
|
Intellia Therapeutics, Inc. Presents at Leerink?s Global Healthcare Conference 2025, Mar-10-2025 03:00 PM |
Mar. 10 |
|
|
HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target |
Mar. 05 |
MT |
|
Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating |
Mar. 03 |
MT |
|
RBC Cuts Price Target on Intellia Therapeutics to $37 From $47, Keeps Outperform, Speculative Risk |
Feb. 28 |
MT |
|
JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13 |
Feb. 28 |
MT |
|
Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell |
Feb. 27 |
MT |
|
Intellia Therapeutics, Inc., Q4 2024 Earnings Call, Feb 27, 2025 |
Feb. 27 |
|
|
Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Collaboration Revenue $12.9M, vs. FactSet Est of $8.6M |
Feb. 27 |
MT |
|
Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Net Loss $-1.27 a Share, vs. FactSet Est of $-1.33 Loss |
Feb. 27 |
MT |
|
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 27 |
CI |
|
Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade |
Jan. 27 |
MT |
NTLA: Dynamic Chart
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
